Anika Therapeutics (ANIK) Income towards Parent Company (2010 - 2026)

Anika Therapeutics (ANIK) has reported Income towards Parent Company for 17 consecutive years, with $3.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Income towards Parent Company rose 182.23% year-over-year to $3.3 million in Q2 2026; TTM through Jun 2026 was -$2.1 million, a 96.57% increase from a year earlier, with the FY2025 full-year figure at -$9.2 million, up 84.07% from the prior year.
• Income towards Parent Company was $3.3 million for Q2 2026 at Anika Therapeutics, up from -$5.1 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $16.2 million in Q4 2023 and troughed at -$29.9 million in Q3 2024.
• A 5-year average of -$4.0 million and a median of -$3.4 million in 2022 frame the typical range for Income towards Parent Company.
• Across the five-year window, Income towards Parent Company soared 411.38% in 2022 and tumbled 4432.95% in 2025, its largest moves.
• Over 5 years, Income towards Parent Company stood at $10.1 million in 2022, then soared by 60.71% to $16.2 million in 2023, then sank by 243.22% to -$23.2 million in 2024, then surged by 108.53% to $2.0 million in 2025, then jumped by 65.82% to $3.3 million in 2026.
• The last three Income towards Parent Company figures came in at $3.3 million (Q2 2026), -$5.1 million (Q1 2026), and $2.0 million (Q4 2025), per Business Quant data.